{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:35:33Z","timestamp":1740108933095,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Clinical stage I (CSI) testicular germ cell tumors (TGCT) represents disease confined to the testis without metastasis and CSIS is defined as persistently elevated tumor markers (TM) after orchiectomy, indicating subclinical metastatic disease. This study aims at assessing clinical characteristics and oncological outcome in CSIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from five tertiary referring centers in Germany were screened. We defined correct classification of CSIS according to EAU guidelines. TM levels, treatment and relapse-free survival were assessed and differences between predefined groups (chemotherapy, correct\/incorrect CSIS) were analyzed with Fisher\u2019s exact and Chi-square test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 2616 TGCT patients, 43 (1.6%) were CSIS. Thereof, 27 were correctly classified (cCSIS, 1.03%) and 16 incorrectly classified (iCSIS). TMs that defined cCSIS were in 12 (44.4%), 10 (37%), 3 (11.1%) and 2 (7.4%) patients AFP, \u00df-HCG, AFP plus \u00df-HCG and LDH, respectively. In the cCSIS group, six patients were seminoma and 21 non-seminoma. Treatment consisted of active surveillance, carboplatin-mono AUC7 and BEP (bleomycin, etoposide and cisplatin). No difference between cCSIS and iCSIS with respect to applied chemotherapy was found (<jats:italic>p<\/jats:italic>\u2009=\u20090.830). 5-year relapse-free survival was 88.9% and three patients (11%) in the cCSIS group relapsed. All underwent salvage treatment (3xBEP) with no documented death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Around 1% of all TGCT were classified as cCSIS patients. Identification of cCSIS is of critical importance to avoid disease progression and relapses by adequate treatment. We report a high heterogeneity of treatment patterns, associated with excellent long-term survival irrespective of the initial treatment approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-021-03889-x","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T15:04:48Z","timestamp":1638457488000},"page":"327-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-3593","authenticated-orcid":false,"given":"Maximilian Peter","family":"Brandt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. P.","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Syring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruckes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. U.","family":"Schmelz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dotzauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hiester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nettersheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Loosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Paffenholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"GESRU Academics Testis, Penile Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian Peter","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Syring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nettersheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Paffenholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"6","key":"3889_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","volume":"68","author":"P Albers","year":"2015","unstructured":"Albers P et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054\u20131068","journal-title":"Eur Urol"},{"key":"3889_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K.) (2019) AWMF, S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. 2019 (Langversion 1.0)"},{"issue":"2","key":"3889_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.eururo.2017.06.013","volume":"73","author":"SC Kamran","year":"2018","unstructured":"Kamran SC et al (2018) Contemporary treatment patterns and outcomes for clinical stage IS testicular cancer. Eur Urol 73(2):262\u2013270","journal-title":"Eur Urol"},{"issue":"h8","key":"3889_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.urolonc.2014.04.004","volume":"32","author":"KD Faber","year":"2014","unstructured":"Faber KD et al (2014) Validation of surveillance, epidemiology, and end results TNM staging for testicular germ cell tumor. Urol Oncol 32(h8):1341\u20131346","journal-title":"Urol Oncol"},{"issue":"4","key":"3889_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/annonc\/mdx012","volume":"28","author":"KM Wymer","year":"2017","unstructured":"Wymer KM et al (2017) Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol 28(4):899\u2013902","journal-title":"Ann Oncol"},{"issue":"4","key":"3889_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/cncr.23233","volume":"112","author":"A Dash","year":"2008","unstructured":"Dash A et al (2008) The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 112(4):800\u2013805","journal-title":"Cancer"},{"issue":"4","key":"3889_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(01)66248-7","volume":"155","author":"S Culine","year":"1996","unstructured":"Culine S et al (1996) Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 155(4):1296\u20131298","journal-title":"J Urol"},{"issue":"2","key":"3889_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.canep.2014.02.003","volume":"38","author":"KA Ahmed","year":"2014","unstructured":"Ahmed KA, Wilder RB (2014) Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis. Cancer Epidemiol 38(2):124\u2013128","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"3889_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/sj.bjc.6603087","volume":"94","author":"C Ackers","year":"2006","unstructured":"Ackers C, Rustin GJ (2006) Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours. Br J Cancer 94(9):1231\u20131232","journal-title":"Br J Cancer"},{"issue":"2","key":"3889_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3892\/etm.2011.197","volume":"2","author":"K Kotoh","year":"2011","unstructured":"Kotoh K et al (2011) Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. Exp Ther Med 2(2):195\u2013199","journal-title":"Exp Ther Med"},{"issue":"1","key":"3889_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.035","volume":"358","author":"K Augoff","year":"2015","unstructured":"Augoff K, Hryniewicz-Jankowska A, Tabola R (2015) Lactate dehydrogenase 5: an old friend and a new hope in the war on cancer. Cancer Lett 358(1):1\u20137","journal-title":"Cancer Lett"},{"issue":"6","key":"3889_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/br.2015.500","volume":"3","author":"S Mythili","year":"2015","unstructured":"Mythili S, Malathi N (2015) Diagnostic markers of acute myocardial infarction. Biomed Rep 3(6):743\u2013748","journal-title":"Biomed Rep"},{"key":"3889_CR13","doi-asserted-by":"publisher","first-page":"5030349","DOI":"10.1155\/2019\/5030349","volume":"2019","author":"KP Dieckmann","year":"2019","unstructured":"Dieckmann KP et al (2019) Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int 2019:5030349","journal-title":"Biomed Res Int"},{"issue":"3","key":"3889_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000478706","volume":"99","author":"KP Dieckmann","year":"2017","unstructured":"Dieckmann KP et al (2017) Pure testicular seminoma with non-pathologic elevation of alpha fetoprotein: a case series. Urol Int 99(3):353\u2013357","journal-title":"Urol Int"},{"issue":"10","key":"3889_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000342695","volume":"35","author":"P Patel","year":"2012","unstructured":"Patel P, Balise R, Srinivas S (2012) Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance. Onkologie 35(10):588\u2013591","journal-title":"Onkologie"},{"issue":"16","key":"3889_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.18.01480","volume":"37","author":"KP Dieckmann","year":"2019","unstructured":"Dieckmann KP et al (2019) Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 37(16):1412\u20131423","journal-title":"J Clin Oncol"},{"issue":"1","key":"3889_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","volume":"33","author":"C Kollmannsberger","year":"2015","unstructured":"Kollmannsberger C et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33(1):51\u201357","journal-title":"J Clin Oncol"},{"issue":"9","key":"3889_CR18","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/annonc\/mdq026","volume":"21","author":"T Tandstad","year":"2010","unstructured":"Tandstad T et al (2010) Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 21(9):1858\u20131863","journal-title":"Ann Oncol"},{"issue":"12","key":"3889_CR19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","volume":"17","author":"T Gilligan","year":"2019","unstructured":"Gilligan T et al (2019) Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(12):1529\u20131554","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"3889_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0022-5347(17)32830-6","volume":"152","author":"BE Davis","year":"1994","unstructured":"Davis BE et al (1994) The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152(1):111\u2013113 (discussion 114)","journal-title":"J Urol"},{"issue":"7","key":"3889_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1200\/JCO.1994.12.7.1390","volume":"12","author":"SB Saxman","year":"1994","unstructured":"Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12(7):1390\u20131393","journal-title":"J Clin Oncol"},{"issue":"4","key":"3889_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/JU.0000000000000366","volume":"202","author":"J Aparicio","year":"2019","unstructured":"Aparicio J et al (2019) Treatment and outcome of patients with stage IS testicular cancer: a retrospective study from the Spanish germ cell cancer group. J Urol 202(4):742\u2013747","journal-title":"J Urol"},{"issue":"13","key":"3889_CR23","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","volume":"27","author":"T Tandstad","year":"2009","unstructured":"Tandstad T et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122\u20132128","journal-title":"J Clin Oncol"},{"issue":"7","key":"3889_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","volume":"27","author":"T Tandstad","year":"2016","unstructured":"Tandstad T et al (2016) Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol 27(7):1299\u20131304","journal-title":"Ann Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03889-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T13:23:00Z","timestamp":1647264180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03889-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no financial or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the local ethics committee of cologne was obtained (No. 18-008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}